Simon Chivers
Impact in
- Oncology top 10%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
-
- Biosimilars and Bioanalytical Methods
- Immune Cell Function and Interaction
Papers in
- Oncology 12
- CAR-T cell therapy research 9
- HER2/EGFR in Cancer Research 3
-
- Cancer therapeutics and mechanisms 5
- Co-authors
- Francesca Zammarchi (13 shared papers)Patrick H. van Berkel (12 shared papers)John A. Hartley (10 shared papers)Karin Havenith (11 shared papers)Simon Corbett (7 shared papers)Lauren Adams (6 shared papers)David G. Williams (6 shared papers)Philip W. Howard (4 shared papers)
- Journals
- Cancer Research (5 papers)Blood (3 papers)Drug Discovery Today (1 paper)Regulatory Toxicology and Pharmacology (1 paper)Molecular Cancer Therapeutics (1 paper)
- Partner nations
- United KingdomSwitzerlandUnited States
In The Last Decade
Simon Chivers
21 papers receiving 600 citations
Peers
Comparison fields: 5 of 69
- Oncology 301
- Immunology 148
- Radiology, Nuclear Medicine and Imaging 152
- Small Animals 43
- Pathology and Forensic Medicine 85
Countries citing papers authored by Simon Chivers
This map shows the geographic impact of Simon Chivers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Chivers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Chivers more than expected).
Fields of papers citing papers by Simon Chivers
This network shows the impact of papers produced by Simon Chivers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Chivers. The network helps show where Simon Chivers may publish in the future.
Co-authors
The 25 scholars most cited alongside Simon Chivers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 132 | |
| 2 | 2018 | 93 | |
| 3 | 2014 | 62 | |
| 4 | 2020 | 61 | |
| 5 | 2017 | 58 | |
| 6 | 2009 | 53 | |
| 7 | 2013 | 43 | |
| 8 | Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers | 2022 | 29 |
| 9 | 2016 | 15 | |
| 10 | 2016 | 14 | |
| 11 | 2016 | 12 | |
| 12 | 2016 | 11 | |
| 13 | 2015 | 9 | |
| 14 | 2022 | 9 | |
| 15 | 2024 | 8 | |
| 16 | 2018 | 5 | |
| 17 | 2018 | 5 | |
| 18 | 2019 | 3 | |
| 19 | 2022 | 1 | |
| 20 | 2017 | 1 |
About Simon Chivers
Simon Chivers is a scholar working on Oncology, Molecular Biology, Neurology, Immunology and Organic Chemistry, having authored 21 papers that have together received 625 indexed citations. Recurring topics across this work include CAR-T cell therapy research (9 papers), Neuroblastoma Research and Treatments (5 papers), Cancer therapeutics and mechanisms (5 papers), Synthesis and pharmacology of benzodiazepine derivatives (4 papers), HER2/EGFR in Cancer Research (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Lymphoma Diagnosis and Treatment (2 papers) and Biosimilars and Bioanalytical Methods (2 papers). The work is most often cited by research in Oncology (301 citations), Immunology (148 citations), Radiology, Nuclear Medicine and Imaging (152 citations), Small Animals (43 citations) and Pathology and Forensic Medicine (85 citations). Simon Chivers has collaborated with scholars based in United Kingdom, Switzerland and United States. Frequent co-authors include Francesca Zammarchi, Patrick H. van Berkel, John A. Hartley, Karin Havenith, Simon Corbett, Lauren Adams, David G. Williams, Philip W. Howard, Peter Tyrer and Arnaud Tiberghien. Their work appears in journals such as Cancer Research, Blood, Drug Discovery Today, Regulatory Toxicology and Pharmacology and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.